Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer (TrasTUCAN)
Single Arm Phase II Study of the Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer TrasTUCAN Study
Sponsor: Seagen Inc.
Terminated
The study was closed early due to safety concerns and an unfavorable benefit-risk balance. Unexpected high neutropenia rates required a costly sub-study, which was not feasible, forcing the sponsor to terminate the trial prematurely.
Other terminated trials from Seagen Inc.
- Appendiceal Adenocarcinoma · Phase PHASE1 · Mar 2024
- Carcinoma, Non-Small-Cell Lung · Phase PHASE1 · Dec 2023
- Bladder Cancer · Phase PHASE1 · Dec 2023
- Multiple Myeloma · Phase PHASE1 · Nov 2023
- Colorectal Cancer · Phase PHASE1 · Mar 2023
More terminations from Seagen Inc.
Listed as NCT05583110, this PHASE2 trial focuses on HER2-positive Metastatic Breast Cancer and Locally Advanced HER2 Positive Breast Carcinoma and remains terminated or withdrawn. Sponsored by Seagen Inc., it has been updated 10 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jul 2023 — May 2024 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jul 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Seagen Inc.
- Spanish Breast Cancer Research Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Barcelona, Spain , Bádajoz, Spain , Cadiz, Spain , Córdoba, Spain , Donostia / San Sebastian, Spain , Jaén, Spain , Las Palmas de Gran Canaria, Spain , Madrid, Spain , Málaga, Spain and 7 more locations